GW Pharmaceuticals tests epilepsy drug in man as FDA softens stance

A.B. | ShareCast | 18 Sep, 2013 11:09 - Updated: 11:59 | | |

Drugs

Cannabis-derived drug developer GW Pharmaceuticals has begun human trials of its epilepsy treatment.

The AIM- and Nasdaq-listed company said the novel drug candidate, currently named GWP42006, was one of its most promising and looked to have significantly fewer side effects than currently approved anti-epileptic drugs.

Dr. Stephen Wright, Director of Research and Development at the company said advancing GWP42006 to a first dose in man was a significant milestone in the development of this candidate.

“The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," he added.

"We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Research with the Reading School of Pharmacy in Buckinghamshire has shown that GWP42006 not only exerts significant ability to treat seizures in a wide range of preclinical models of seizure and epilepsy, but is also better tolerated by patients compared to existing anti-epileptic drugs.

The company has been encouraged by recent interest in its products in the US. That arose after the pharmaceutical regulator, the Food and Drug Administration [FDA], allowed US epilepsy specialists and patient organizations to carry out treatment on a small number of pediatric epilepsy patients with a cannabidiol [CBD] formulation supplied by GW. These activities may generate initial evidence to add CBD as a further pipeline candidate for clinical evaluation in epilepsy.

Recent third quarter showed net cash of $66.3m thanks to a US IPO in May that raised $30.4m.

Shares in GWP were up 1.4% to 72p at 11:12 on Wednesday.

OH

More news

17:16 US close: Markets rise, on the back of Microsoft and Procter&Gamble

US stocks registered moderate gains on Friday, despite reports of a first Ebola case in New York, while the focus remained on company results.

24 Oct Fitch affirms Spain and Italy at BBB+, both with stable outlook

24 Oct Three people hospitalised after shooting at Seattle high school

24 Oct Apple iTunes sales plummet

iTunes sales have fallen 13% to 14% world-wide since January 2014, underlining the precarious nature of the music industry’s recovery.

24 Oct GoPro shares slumps as Oppenheimer initiates covearege of the stock at sell

24 Oct S&P upgrades Cyprus on strong budget performance

Rating agency Standard & Poor's has upgraded European economic struggler Cyprus, citing a strong budgetary performance.

24 Oct Market overview: S&P downgrades Tesco

1630:Close The Footsie ended the session lower ahead of this weekend’s ECB stress tests and after an initial feint lower in US stocks. Significantly, on Friday ECB president Mario Draghi sounded a clarion call to action, warning leaders from the European Union that a "joint effort" is required to avoid a "relapse into recession." Tullow continued to reel under the pressure of low oil prices but Pearson did worst on the top flight index after announcing that its CFO was leaving. Intercontinental Hotels Group was also to be seen lower following reports overnight of an Ebola infection in NY. Heading the other way was Shire. The firm updated investors on its third quarter results. Tesco managed to hold on to the nearest level of technical support at 168p – at least for now. FTSE 100 down 30 to 6,388.7.

24 Oct US open: Markets fluctuate amid renewed Ebola fears, while Ford and Amazon drop

US stocks were largely unchanged on Friday, as investors looked to be worried by reports of the first Ebola case in New York, while the focus remained on company results.

24 Oct City's mayor says NYC fully prepared to deal with Ebola

Bill De Blasio, New York City's mayor, said the city was "fully prepared" to deal with the Ebola virus.

24 Oct Europe close: Stocks end on a mixed note

European equities finished the Friday session on a mixed note as investors kept their cards close to their chests ahead of the European Central Bank’s (ECB) ‘stress tests’ which were due out this weekend.

Advertising

HIGHLIGHTS

New York
Ebola latest: The NYPD has been photographed throwing hazmat suits and gloves into public bins

Welcome to our rolling coverage of the Ebola crisis. Refresh for updates on the outbreak as they happen.

VIDEOS

EUR/USD: continues its clearly bearish trend
REGISTER NOW!